Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT06331598
- Locations
- 🇪🇸
Hospital Universitario Virgen; Servicio de Oncologia, Sevilla, Spain
🇪🇸Hospital Universitari Vall dHebron; Oncology, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT06274515
- Locations
- 🇧🇪
AZ Delta (Campus Rumbeke), Roeselare, Belgium
🇫🇮Tampere University Hospital; Dept of Oncology, Tampere, Finland
🇩🇪KEM/Evang. Kliniken Essen Mitte gGmbH; Klinik für Internistische Onkologie / Hämatologie, Essen, Germany
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT06267001
- Locations
- 🇨🇳
Ningbo No.2 Hospital, Ningbo, China
🇮🇹Instituto Europeo di Oncologia, Milano, Lombardia, Italy
🇮🇹Azienda U.S.L. 21 - Presidio Ospedaliero S. Spirito; U.O. Di Oncologia Clinica, Casale Monferrato, Piemonte, Italy
A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT06189508
- Locations
- 🇳🇿
New Zealand Clinical Research - Auckland, Auckland, New Zealand
🇳🇿New Zealand Clinical Research - Christchurch, Christchurch, New Zealand
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT06176352
- Locations
- 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇦🇺South West Retina, Liverpool, New South Wales, Australia
🇦🇺Strathfield Retina Clinic, Strathfield, New South Wales, Australia
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT06128564
- Locations
- 🇪🇸
Hospital Sant Joan De Deu, Esplugues De Llobregas, Barcelona, Spain
🇫🇷Hôpital Necker-Enfants Malades; Service de neuropédiatrie, Paris, France
🇬🇧Great Ormond Street Hospital for Children, London, United Kingdom
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT06106828
- Locations
- 🇨🇦
Serac Eye and Skin Care Centre, Calgary, Alberta, Canada
🇺🇸Plastics-Orbit-Neuro, San Diego, California, United States
🇺🇸Eye Care Center of Northern Colorado PC, Longmont, Colorado, United States
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT06094010
- Locations
- 🇺🇸
Velocity Clinical Research at Primary Pediatrics Macon, Macon, Georgia, United States
🇺🇸Kentucky Pediatric Research Center, Bardstown, Kentucky, United States
🇺🇸Velocity Clinical Research, Salt Lake City, West Jordan, Utah, United States
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT06084936
- Locations
- 🇦🇺
Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia
🇦🇺Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia
🇦🇺Epworth Hospital, Richmond, Victoria, Australia
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1050
- Registration Number
- NCT06065748
- Locations
- 🇺🇸
Sutter Health Medical Center, Sacramento, California, United States
🇩🇪Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie, Bamberg, Germany
🇬🇷Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece